Vaccine development is a long and complicated process, always requiring over ten years. Vaccines can be prophylactic or therapeutic. A prophylactic vaccine is to prevent a future infection by a natural pathogen, while a therapeutic vaccine is always against cancer. Vaccines are often dead or inactivated native pathogen or pathogen analog. Here, we give a brief introduction to the applications of exosomes in vaccine development. Besides, to aid in exosome research, Creative Biolabs is offering a comprehensive array of exosome-related services to help the vaccine development.
A desirable vaccine should be safe, stable, and molecularly defined. Several types of novel vaccines in development include dendritic cell vaccine, recombinant vector vaccine, DNA vaccine, and peptide vaccine.
Exosomes are cell-derived vesicles that can be produced by many cell types, including dendritic cell, tumor cell, ascitic cell. Creative Biolabs offers a full range of exosome-related services for customers to facilitate the research of exosomes for vaccine development.
Dendritic cell-derived exosomes have MHC I, MHC II, and costimulatory molecules expressed on their surface, which makes them act as potent vaccine if synthetic peptides or some interesting pathogens epitope are combined to the MHC I and MHC II.
Tumor cell-derived exosomes express membrane-associated tumor-specific molecules, making them potential vaccine for cancer therapies via strengthening the immune response aginst cancer.
In patients with ovarian cancer and some other cancer, ascitic fluids are the tumor exosome sources. Ascitic cell-derived exosomes may also carry tumor-specific antigens, which makes it a potential choice to develop new vaccine.
Please feel free to contact us if you are interested in our services.